AOD-9604 legal status: is it legal to buy and use in 2026?

Last updated 2026-07-25

Is AOD-9604 FDA approved?

No. There is no AOD-9604 product listed in Drugs@FDA, the agency's own database of approved drug products ^[1]. That means no manufacturer has ever taken it through a New Drug Application and won approval for any use, obesity or otherwise. This isn't a technicality or an oversight. AOD-9604 was actually developed for obesity and went through real human trials in the 2000s, sponsored by the Australian company Metabolic Pharmaceuticals. The compound reached the clinic and then stalled there. We'll get into why in the trial section below, but the short version is that it never generated the efficacy data needed to file for approval anywhere, more than the US. So when you see AOD-9604 marketed for fat loss, understand you're looking at a compound with zero approved indications, sold outside the FDA-approved drug system entirely.

Why isn't AOD-9604 on the FDA's compounding list?

FDA maintains two lists that matter here: the 503A bulk drug substances list for traditional compounding pharmacies ^[2], and the 503B list for larger outsourcing facilities ^[3]. AOD-9604 is not on either one, as of the current versions published in the Federal Register and cited on FDA's own bulk-substances pages ^[4]. Those lists exist because of Section 503A of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 353a ^[5], which lets pharmacies compound drugs from bulk substances under specific conditions, including that the substance appears on FDA's approved bulks list or meets narrower exceptions. A compound not on that list, and not part of an FDA-approved drug, sits outside the legal compounding pathway. FDA has an open nominations process where substances can be proposed for the list ^[6], and AOD-9604 has not made it through that process to inclusion. Practically, this means a US compounding pharmacy that mixes up AOD-9604 and dispenses it as a drug for a named patient is operating outside the 503A framework. That's a different legal posture than a supplement seller shipping it labeled "not for human consumption."

So how is AOD-9604 being sold at all?

Almost everything on the market ships under a research-use-only label. Sellers lean on the idea that they're providing a research chemical, not a drug intended for human use, which shifts the compliance burden onto how the product is marketed and labeled. FDA's own regulation on intended use, 21 CFR 201.128, is the relevant test here ^[7]. It says a product's intended use is determined by objective evidence, including labeling, advertising, and how it's promoted, more than the words printed on the vial. Regulators can look past a "research use only" sticker if a seller is clearly marketing the product for humans to inject for fat loss. That gap between label and marketing behavior is exactly where most peptide sellers live, and it's not a comfortable place to build a purchase decision on. If you're weighing where to actually source from, a provider-reviewed route at least gives you a paper trail and consistent handling, even though the underlying legal status of the compound itself doesn't change.

What did AOD-9604's human obesity trials actually show?

This is the part that matters more than any regulatory nuance, and it's the reason we're not going to sugarcoat this compound. AOD-9604 is a fragment of human growth hormone, specifically the region thought to carry HGH's fat-metabolizing (lipolytic) activity without the growth-promoting effects. The idea was elegant on paper: keep the fat-burning signal, drop the parts that cause acromegaly-type growth side effects. A 2004 review of AOD-9604 as a metabolic candidate summarized the compound's proposed mechanism and its early trial trajectory in obesity ^[8]. The compound went through Phase II human obesity trials sponsored by Metabolic Pharmaceuticals. A 2006 review of obesity drugs in clinical development documented AOD-9604 as one of several candidates in that pipeline at the time ^[9]. What that pipeline review and the broader trial record show is a compound that did not produce weight-loss results that separated convincingly from placebo. The company's own later public statements confirmed the fragment failed to clear the bar needed to advance toward approval, and it was effectively shelved as an obesity drug. That's the central fact anyone researching this peptide needs to sit with. A real biotech company ran real Phase II trials in real obese human subjects, and the fat-loss signal wasn't there in a way regulators or the sponsor found convincing enough to continue toward approval.

Why did a plausible-sounding mechanism fail in the clinic?

The honest answer is that mechanism plausibility and clinical efficacy are two different things, and peptide fragments are notorious for looking better in a test tube or a rodent than in a person. AOD-9604 is a 15-amino-acid fragment of the C-terminus of human growth hormone (hGH 176-191). The rationale was that this region drives lipolysis independent of the receptor-binding domains responsible for growth effects. That's a real, testable hypothesis, and it's why the compound got funded into human trials in the first place. It's not junk science. But bioavailability, dosing, and the actual magnitude of lipolytic effect in free-living humans eating normally are a different problem than isolated fat-cell assays. The trial record is what it is: Phase II obesity studies that didn't produce a durable, statistically separated weight-loss result versus placebo. A recent 2026 review of therapeutic peptides in orthopaedic applications references AOD-9604's history as part of the broader peptide development landscape ^[10], and a 2026 sports medicine review covering approved and unapproved peptide therapies for musculoskeletal and performance use similarly catalogs it among compounds without an approved therapeutic claim ^[11]. Neither treats it as a proven fat-loss agent.

Is AOD-9604 banned in sports? Does it show up on drug tests?

AOD-9604 is not currently on WADA's Prohibited List as its own named substance, but it's a growth hormone fragment, and athletes should assume real scrutiny if they're tested in a governed sport. A 2013 study in Drug Testing and Analysis specifically examined whether AOD-9604 interferes with the WADA hGH isoform immunoassay, the test used to catch synthetic growth hormone doping, and found it does not influence that assay ^[12]. That finding matters for a narrow reason: it tells anti-doping labs the fragment won't create a false signal or masking effect on the existing hGH test, not that AOD-9604 itself is undetectable or permitted. Separately, mass spectrometry methods built for detecting peptide doping, including work on screening peptides under 2 kDa by direct urine injection and ion mobility mass spectrometry, are part of the analytical toolkit labs use to catch small peptide drugs generally ^[13]. Broader reviews of detecting peptide drugs and analogs in sports doping describe the ongoing arms race between novel peptides and lab detection methods ^[14], and a related 2014 paper on analytical approaches for emerging therapeutics in doping controls covers similar ground ^[15]. If you compete under any drug-tested federation, don't assume a fragment peptide is a safe loophole. Ask your federation directly.

Is it legal to import or ship AOD-9604 into the US?

This is genuinely murky, and anyone who tells you it's simple is oversimplifying. Products labeled research-use-only and shipped as such generally move through customs without the same scrutiny as an obviously human-use pharmaceutical, but that labeling doesn't retroactively make personal-use injection legal or sanctioned. Customs and FDA both have authority to detain shipments of unapproved drugs represented for human use, particularly injectable peptides crossing international borders. In practice, enforcement against individual buyers of small quantities is inconsistent and mostly not the priority; enforcement against sellers making explicit human-use dosing claims is a different story and where most actual FDA warning letters in the peptide space have landed. The safest posture, if you're going to use it anyway, is a source that's transparent about sourcing, batch testing, and provider review rather than an anonymous storefront making bold human-dosing claims on a research-only label.

How does AOD-9604's legal status compare to tesamorelin or other approved options?

This comparison is where the legal-status question actually becomes a buying decision, so it's worth laying out side by side.

Tesamorelin has an actual FDA approval, and you can look it up directly in Drugs@FDA ^[1]. It's not approved for general fat loss, it's approved for a specific lipodystrophy indication in HIV patients, so it's not a blank check either, but it has real efficacy data behind its approved use. If you're weighing the two, read AOD-9604 vs tesamorelin for the head-to-head on mechanism and evidence quality. GLP-1 drugs like semaglutide and tirzepatide are the current gold standard for pharmaceutical weight loss, with FDA-approved obesity indications backed by large positive Phase III programs. If your actual goal is fat loss with a strong evidence base, that's where the real data lives, not in a fragment peptide that stalled in Phase II twenty years ago.

What does 'research use only' actually mean legally?

It means the seller is representing the product as intended for laboratory research, not human consumption, and that label is the seller's attempt to operate outside FDA's drug regulations. It does not mean the product is legal for you to inject. Under 21 CFR 201.128, intended use isn't just what the label says, it's determined by the totality of evidence: how the product is advertised, what dosing information is provided, what claims accompany it ^[7]. A vial stamped "research use only" sold alongside blog posts about fat-loss dosing protocols is a mismatch regulators can act on, and periodically do, through FDA warning letters to peptide sellers. For you as a buyer, the practical takeaway is that RUO labeling is a legal fiction the industry runs on, not a certification of safety, purity, or legality for personal use. Treat it as neither reassuring nor damning on its own; treat it as an indicator that nobody in the supply chain wants to be the one holding liability for human use.

Should you actually buy AOD-9604, given all this?

Here's the straight answer. The legal status is unresolved and gray, sold under a research label with no FDA approval and no place on the compounding bulks list. That alone doesn't kill the case for trying it, plenty of gray-market compounds get used anyway. What should kill your enthusiasm is the trial record: real Phase II human obesity trials that didn't show weight loss clearing placebo convincingly ^[9]. That's not marketing spin, that's the same conclusion the compound's own sponsor effectively reached when it didn't pursue approval further. If you're set on trying it anyway, at minimum go through a provider-reviewed source rather than an anonymous storefront, because sourcing quality is the one variable you can actually control when the underlying efficacy data is this thin. AOD-9604 Co reviews providers specifically so buyers aren't guessing on purity and handling, but that review process can't manufacture efficacy data that doesn't exist. If your real goal is measurable fat loss backed by strong trial data, look at the approved GLP-1 category first. If you're specifically interested in fragment peptides and lipolysis mechanisms for research purposes, read the AOD-9604 peptide overview and go in with the placebo-controlled trial outcome fully in view, not buried under mechanism talk.

What should you check before buying, given the legal gray area?

A few concrete things actually reduce your risk, even inside a gray-market category. First, check whether the seller provides a certificate of analysis for the specific batch you're buying, not a generic one pulled from a website. Second, look at whether marketing claims stay vague (research applications, cell studies) or drift into explicit human dosing protocols for fat loss, because the latter is the exact pattern FDA's intended-use rule targets ^[7]. Third, understand that reconstitution and storage matter for anything you do end up acquiring; see how to reconstitute AOD-9604 and when to take AOD-9604 if you want the practical handling side covered separately from the legal question. None of this converts a legally gray, efficacy-unproven compound into a safe bet. It just means that if you're going in anyway, you're not adding sourcing risk on top of the trial-data risk that's already baked in.

Frequently asked questions

Is AOD-9604 legal to buy in the United States?

It's sold legally as a research-use-only chemical, but it has no FDA drug approval and isn't on FDA's 503A bulk compounding list ^[1][2]. Buying it for personal human use sits in a gray zone; the product itself isn't federally scheduled as a controlled substance, but marketing it for human fat loss can trigger FDA action against sellers.

Is AOD-9604 FDA approved for weight loss?

No. There is no AOD-9604 listing in Drugs@FDA, the FDA's approved drug products database ^[1]. It went through Phase II human obesity trials in the 2000s that failed to show weight loss clearly separating from placebo, and it was never resubmitted successfully for approval anywhere.

Can a compounding pharmacy legally make AOD-9604?

Not under Section 503A as written. AOD-9604 doesn't appear on FDA's 503A bulk drug substances list ^[2] or the 503B list ^[3], both required references under 21 U.S.C. 353a for legal bulk compounding ^[5]. A pharmacy dispensing it as a compounded drug for a named patient is operating outside that framework.

Does AOD-9604 show up on a drug test?

A 2013 study found AOD-9604 does not interfere with the WADA hGH isoform immunoassay used to detect synthetic growth hormone doping ^[12]. That means it won't mask hGH doping on that specific test, but it doesn't mean the fragment itself is undetectable by other peptide-specific mass spectrometry methods labs use ^[13][14].

Did AOD-9604 pass its human clinical trials?

It reached Phase II obesity trials, but the weight-loss results did not separate convincingly from placebo, and the sponsor did not advance it further toward approval ^[9]. This is the central fact anyone researching AOD-9604 for fat loss needs to know before spending money on it.

What is the difference between AOD-9604 and tesamorelin legally?

Tesamorelin is FDA-approved (as Egrifta) for HIV-associated lipodystrophy, with positive trial data supporting that specific indication. AOD-9604 has no FDA approval for any use and failed to show clear efficacy in its own Phase II obesity trials ^[9]. See the full comparison for mechanism differences.

Why is AOD-9604 sold as 'research use only'?

Sellers use that label to position the product outside FDA's human drug regulations. Under 21 CFR 201.128, intended use is judged by marketing and labeling as a whole, not the label alone ^[7], so RUO wording doesn't automatically make human use legal, it just shifts where enforcement risk sits.

Is AOD-9604 banned by WADA?

AOD-9604 is not clearly named as its own separate entry on WADA's current Prohibited List in the sources reviewed here, but it's a growth hormone fragment and falls into a category anti-doping labs actively screen for using peptide-specific mass spectrometry methods ^[13][14]. Athletes in tested sports should check directly with their federation before use.

Can I legally import AOD-9604 from overseas?

Enforcement against small personal-quantity imports labeled research-use-only is inconsistent and often not prioritized, but FDA and customs retain authority to detain shipments of unapproved drugs represented for human use. Sellers making explicit human-dosing claims face more direct enforcement risk than individual buyers.

What does the fragment theory behind AOD-9604 actually claim?

AOD-9604 is a 15-amino-acid fragment of human growth hormone (region 176-191), theorized to retain HGH's fat-metabolizing activity while dropping the growth-promoting effects tied to acromegaly-type side effects ^[8]. It's a plausible mechanism that got funded into real Phase II obesity trials, but the clinical weight-loss results didn't confirm the lab-level hypothesis ^[9].

Are there safer, better-proven alternatives to AOD-9604 for fat loss?

Yes. GLP-1 receptor agonists like semaglutide and tirzepatide carry FDA approval specifically for chronic weight management, backed by large positive Phase III trials, unlike AOD-9604's stalled Phase II obesity program ^[9]. If measurable, trial-proven fat loss is the goal, that class currently has the strongest human evidence.

Where should I buy AOD-9604 if I decide to try it anyway?

Go through a provider-reviewed source rather than an anonymous storefront, since sourcing quality is the main variable you control given the thin efficacy data. See best place to buy AOD-9604 for what to check on certificates of analysis and batch testing before purchasing.

Sources

1. FDA, Drugs@FDA approved drug products database: No AOD-9604 product is listed as an FDA-approved drug; tesamorelin (Egrifta) is separately listed as approved.
2. 21 CFR 216.23, the final 503A Bulks List: AOD-9604 is not included on the FDA's 503A bulk drug substances list for traditional pharmacy compounding.
3. 21 CFR 216.24, the 503B Bulks List: AOD-9604 is not included on the FDA's 503B bulks list for outsourcing facility compounding.
4. FDA, bulk drug substances used in compounding under section 503A: FDA maintains and publishes the current 503A bulk substances list that AOD-9604 does not appear on.
5. 21 U.S.C. 353a, pharmacy compounding: Section 503A sets the legal conditions, including bulk substance list membership, under which pharmacies may compound drugs.
6. FDA, bulk drug substances nominated for use in compounding (current list): FDA runs a nomination process for adding substances to the compounding bulks list, which AOD-9604 has not cleared.
7. 21 CFR 201.128, meaning of intended uses: A product's intended use for FDA regulatory purposes is judged by labeling, advertising, and marketing as a whole, not label wording alone.
8. Current Opinion in Investigational Drugs, 2004 (PMID 15134286): AOD-9604's proposed mechanism as a fat-metabolizing HGH fragment and its early clinical trajectory in obesity.
9. Current Opinion in Investigational Drugs, 2006 (PMID 16625817): AOD-9604 was documented as an obesity drug candidate in clinical development whose Phase II results did not clearly separate from placebo.
10. JAAOS Global Research & Reviews, 2026 (PMID 41490200): AOD-9604 is catalogued among therapeutic peptides discussed in orthopaedic applications and challenges literature.
11. Sports Medicine, 2026 (PMID 41966639): AOD-9604 is included among unapproved peptide therapies reviewed for musculoskeletal injury and athletic performance use.
12. Drug Testing and Analysis, 2013 (PMID 24124033): AOD-9604 does not influence or interfere with the WADA hGH isoform immunoassay used in anti-doping testing.
13. Journal of Separation Science, 2016 (PMID 26578461): Analytical methods using direct urine injection and ion mobility mass spectrometry can screen for small peptides under 2 kDa in doping control.
14. Expert Review of Proteomics, 2014 (PMID 25382550): Reviews detection methods and ongoing challenges for identifying peptidic drugs and analogs in sports doping control.
15. Journal of Pharmaceutical and Biomedical Analysis, 2014 (PMID 24906629): Describes analytical approaches used to detect emerging non-approved therapeutics, including peptides, in human doping controls.